ArticleScientific reports2020
Improved cis-Abienol production through increasing precursor supply in Escherichia coli.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Advances in the sustainable biosynthesis of valuable terpenoid flavor compounds and precursors in micro-organisms.Biotechnology for biofuels and bioproducts · 2025Review
- Distinct terpene metabolite blends serve as core drivers of consumer aroma preferences in fir Christmas tree species.Scientific reports · 2025Article
- Bacterial biosynthesis of abietane-type diterpene ferruginol from glucose.Microbial cell factories · 2025Article
- Cis-abienol from tobacco trichomes to ambergris-like compounds: advances in biosynthesis, fermentation, and industrial applications.Frontiers in bioengineering and biotechnology · 2025Review
- Biotransformation of tobacco-derived Z-abienol into precursors of ambrox by newly identifiedFrontiers in microbiology · 2025Article
- Biosynthesis of (Engineering in life sciences · 2022Article
- Highly efficient biosynthesis of β-caryophyllene with a new sesquiterpene synthase from tobacco.Biotechnology for biofuels and bioproducts · 2022Article
- Alternative metabolic pathways and strategies to high-titre terpenoid production inNatural product reports · 2022Review
- Co-Production of Isoprene and Lactate by EngineeredMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
cis-Abienol, a natural diterpene-diol isolated from balsam fir (Abies balsamea), can be employed as precursors for the semi-synthesis of amber compounds, which are sustainable replacement for ambergris and widely used in the fragmented industry. This study combinatorially co-expressed geranyl diphosphate synthase, geranylgeranyl diphosphate synthase, Labda-13-en-8-ol diphosphate synthase and diterpene synthase, with the best combination achieving ~ 0.3 mg/L of cis-abienol. An additional enhancement of cis-abienol production (up to 8.6 mg/L) was achieved by introducing an exogenous mevalonate pathway which was divided into the upper pathway containing acetyl-CoA acetyltransferase/HMG-CoA reductase and HMG-CoA synthase and the lower pathway containing mevalonate kinase, phosphomevalonate kinase, pyrophosphate mevalonate decarboxylase and isopentenyl pyrophosphate isomerase. The genetically modified strain carrying chromosomal copy of low genes of the mevalonate with the trc promoter accumulated cis-abienol up to 9.2 mg/L in shake flask. Finally, cis-abienol titers of ~ 220 mg/L could be achieved directly from glucose using this de novo cis-abienol-producing E. coli in high-cell-density fermentation. This study demonstrates a microbial process to apply the E. coli cell factory in the biosynthesis of cis-abienol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.